Skip to content
Tenfell
Awarded contract
Published 30 Sep 2022

NHS National Generic Pharmaceuticals - Lenalidomide

NHS England · London

Key facts

Awarded
30 Aug 2022
Contract starts
31 Aug 2022
Contract ends
31 Aug 2023
Procedure
Other -
Buyer type
Central government

Awarded to 14 suppliers

SupplierValue
Ranbaxy (UK) Ltd—
Teva UK Ltd—
Sandoz Ltd—
Thornton & Ross Ltd—
Wockhardt UK Limited—
Accord-UK Ltd—
Mylan—
Zentiva Pharma UK Ltd—
Amarox Limited—
Glenmark Pharmaceuticals Europe Ltd—
Mercury Pharmaceuticals Limited—
Bristol Myers Squibb—
Morningside Pharmaeuticals—
Piramal Critical care Limited—

Description

Invitation to offer for NHS National Generic Pharmaceuticals - Lenalidomide Offer reference number: CM/PHG/21/5638 Period of framework agreement: 01/09/2022 to 31/08/2023 (12 months) with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months.

Potential periods of call-offs under the framework agreement: Lenalidomide: ALL REGIONS: 01/09/2022 to 31/08/2023 (12 months)

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.